TABLE 2.
Short-term efficacy of HDPC against established L. infantum infection in BALB/c micea
| Treatment group | Body wt (g) | Relative wt (%)b
|
Amastigote load, LDU (106) (% efficacy)c
|
||
|---|---|---|---|---|---|
| Liver | Spleen | Liver | Spleen | ||
| HDPC | 23.2 ± 0.8 | 5.6 ± 0.4 | 1.4 ± 0.2 | 8.8 ± 9.6 (93.8) | 2.2 ± 1.8 (77.9) |
| MEGAN | 24.2 ± 0.9 | 5.8 ± 0.3 | 1.4 ± 0.2 | 21.7 ± 20.5 (84.8) | 4.5 ± 2.3 (54.7) |
| NTC | 24.6 ± 0.6 | 6.0 ± 0.5 | 1.4 ± 0.2 | 142.2 ± 75.7 | 9.8 ± 6.0 |
a
Mice, intravenously inoculated with 108 stationary-phase L. infantum promastigotes/mouse on D0, were treated for 5 days, starting D42, with HDPC (20 mg/kg of body weight/day, oral administration) or MEGAN (200 mg/kg of body weight/day, subcutaneous injection) or were left untreated. Mice were examined 3 days later (D49). Data are means ± SD for 10 mice in each group.
b
Organ weight/body weight.
c
LDU, number of amastigotes per 1,000 nucleated cells × organ weight (in grams) × 2 × 105. Percent efficacy, [1 − (mean amastigote load in treated mice/mean amastigote load in control mice)] × 100.